Pulse Biosciences Appoints Jon Skinner as Chief Financial Officer

On January 31, 2025, Pulse Biosciences, Inc. (NASDAQ: PLSE) announced the appointment of Jon Skinner as the company’s Chief Financial Officer (CFO), effective February 3, 2025. Alongside his role as CFO, Mr. Skinner will serve as the principal financial officer of the company.

Mr. Skinner brings a wealth of experience to Pulse Biosciences, having most recently served as Vice President, FP&A and Investor Relations at Copeland, a private equity-backed industrial company. His previous roles include Vice President, Finance and Corporate Development at Imperative Care, where he played a pivotal part in M&A activities and strategic partnerships. Prior to this, he held positions at Teleflex and other esteemed companies within the industry.

As part of his appointment, Mr. Skinner has entered into an Employment Agreement with Pulse Biosciences. The agreement stipulates an annual base salary of $400,000, an annual target bonus of 50% of his base salary based on performance objectives, eligibility for employee benefit plans, and a sign-on bonus of up to $56,000.

In addition, Pulse Biosciences awarded Mr. Skinner a stock option to purchase up to 300,000 shares of the company’s common stock, with a ten-year term. The stock option will vest based on the achievement of certain performance objectives linked to the company’s market capitalization and revenue targets.

Furthermore, Mr. Skinner has agreed to the company’s standard inventions assignment, confidentiality, and non-competition agreement, as well as its indemnification agreement for officers and directors.

Pulse Biosciences released a press statement on February 4, 2025, regarding the appointment of Mr. Skinner as CFO, which is attached as Exhibit 99.1 to the Current Report on Form 8-K filed with the Securities and Exchange Commission.

This information is provided under Item 7.01 of the Current Report on Form 8-K and is intended to be furnished. The Employment Agreement with Mr. Skinner and the press release are filed as Exhibits 10.1 and 99.1, respectively.

For a more comprehensive understanding of the terms and conditions of Mr. Skinner’s Employment Agreement, please refer to the complete document filed with the Securities and Exchange Commission.

The Company’s Chief Executive Officer, Paul A. LaViolette, signed the report on February 4, 2025, in accordance with the Securities Exchange Act of 1934.

The original report is available for reference on the SEC’s website or Pulse Biosciences’ investor relations portal.

This article was generated by an automated content engine and was reviewed by a human editor prior to publication. For additional information, read Pulse Biosciences’s 8K filing here.

About Pulse Biosciences

Pulse Biosciences, Inc operates as a novel bioelectric medicine company. The company offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue to treat a various medical condition by using its Nano-Pulse Stimulation technology.